【摘要】 目的 系统评价地黄饮子联合西药治疗帕金森病的临床疗效。方法 检索PubMed、Embase、Web of Science、CNKI、维普、中国生物医学文献数据库(CBM)及万方数据库中关于地黄饮子联合西药治疗帕金森病的随机对照研究(RCT)，检索时间从建库至2024年11月，根据纳入排除标准筛选文献，使用Cochrane偏倚风险评估工具进行文献质量评价并提取资料，采用Review Manager 5.4软件进行Meta分析。结果 最终纳入12项临床随机对照研究，共916例帕金森病患者。Meta分析结果显示：与对照组比较，治疗组服用地黄饮子能明显提高帕金森病治疗的总有效率[OR=4.40,95% CI (2.86,6.77),P<0.000 01]；改善统一帕金森病评分量表(UPDRS)评分[MD=-10.26,95% CI (-15.98,-4.54),P=0.000 4]、UPDRS Ⅲ评分[MD=-5.83,95% CI (-7.11,-4.54),P<0.000 01]、CSS评分[MD=-4.36,95% CI (-5.31,-3.41),P<0.000 01]、PDQ39评分[MD=-6.64,95% CI (-11.16,-2.13),P=0.004]、NMSS评分[MD=-8.02,95% CI (-15.77,-0.27),P<0.000 01]、SCOPA-AUT评分[MD=-1.38,95% CI (-1.89,-0.87),P<0.000 01]。不良反应率[OR=0.60,95% CI (0.23,1.59),P=0.30]。结论 地黄饮子联合西药治疗帕金森病对比单纯西药治疗有更好的临床疗效。更多还原

【Abstract】 Objective To systematically evaluate the efficacy of Dihuang Yinzi combined with western medicine in the treatment of Parkinson’s disease.Methods To search PubMed,Embase,Web of Science,CNKI,VIP,Wanfang database and China Biology Medicine disc (CBM) for randomized controlled trails (RCTs) on the treatment of Parkinson’s disease with Dihuang Yinzi,and the searching time was from the establishment of the database to November 2024,and the literature was screened according to the inclusion and exclusion criteria.The Cochrane Risk of Bias Assessment Tool was used to evaluate the quality of literature and extract the information,and Review Manager 5.4 software was used to perform Meta-analysis.Results Finally,12 clinical RCTs and 916 Parkinson’s disease patients were included.Meta-analysis results showed that,compared with the control group,the administration of Dihuang Yinzi in the treatment group significantly increased the overall effective rate of Parkinson’s disease treatment[OR=4.40,95% CI (2.86,6.77),P < 0.000 01];improved Unified Parkinson’s Disease Rating Scale score[MD=-10.26,95% CI (-15.98,-4.54),P=0.000 4],UPDRS III score[MD=-5.83,95% CI (-7.11,-4.54),P < 0.000 01],CSS score[MD=-4.36,95% CI (-5.31,-3.41),P < 0.000 01],PDQ39 score[MD=-6.64,95% CI (-11.16,-2.13),P=0.004],NMSS score[MD=-8.02,95% CI (-15.77,-0.27),P <0.000 01],SCOPA-AUT score[MD=-1.38,95% CI (-1.89,-0.87),P < 0.000 01].Adverse reaction rate[OR=0.60,95% CI (0.23,1.59),P=0.30].Conclusion Dihuang Yinzi combined with western medicine has better clinical efficacy in the treatment of Parkinson’s disease than western medicine alone.更多还原